Atlas Trials

Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer

Clinical trial NCT05810792 · NOT_YET_RECRUITING

Trial details

NCT number
NCT05810792
Sponsor
Sahlgrenska University Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic CancerSurgeryMetastasisImmunosuppression
Start date
2024-04-01
Primary completion
2027-04-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.